For many early-stage medical device companies, the biggest risks are not merely technical. They are commercial and clinical. It is common for a team to build something that works, only to realize it does not fit into real-world healthcare workflows or purchasing decisions.

The NSF I-Corps Program, created by the National Science Foundation, was designed to address this gap. Over time, it has become one of the most valuable early steps for medtech founders who want to validate their ideas before committing significant time and capital to development.

What is the NSF I-Corps program?

I-Corps is a national program that helps researchers and entrepreneurs explore whether their technology solves a real problem in the market. It does not focus on building the product itself. Instead, it focuses on understanding the people who would use it, pay for it, and decide whether it gets adopted.

Teams work through a structured curriculum centered on customer discovery. That means speaking directly with stakeholders and testing assumptions in real conversations.

Founders learn how to:

• Identify the true customer and end user
• Validate clinical and economic value
• Understand reimbursement and adoption barriers
• Refine how they communicate their solution

Why I-Corps is especially relevant for medtech

Healthcare is a complex market. A single product may need to satisfy clinicians, administrators, procurement teams, and payers. Each group has different priorities, and missing one of them can slow or stop adoption.

I-Corps pushes teams to engage with this complexity early instead of relying on assumptions.

Customer discovery in a complex environment

In medtech, the person using a device is often not the one buying it. A surgeon may want a new tool, but a hospital system still has to approve the purchase.

Through I-Corps, teams typically conduct a large number of interviews with stakeholders such as:

• Physicians and clinicians
• Hospital administrators
• Procurement and purchasing teams
• Patients and caregivers

These conversations reveal how decisions are actually made and where a product fits into existing workflows. Many founders enter the program with a narrow view of their customer and leave with a much broader understanding of the buying process.

Validating clinical and economic value early

A successful medtech product needs to demonstrate both clinical benefit and economic value.

I-Corps helps teams test these assumptions before investing heavily in development. This often leads to important insights such as:

• Whether a procedure is already optimized
• If hospitals are willing to pay for incremental improvements
• How reimbursement impacts adoption
• What outcomes actually matter to decision makers

Identifying these factors early can prevent costly missteps later.

Shaping regulatory and development strategy

I-Corps is not a regulatory program, but it can strongly influence how teams think about regulatory strategy.

By understanding how similar products are evaluated and adopted, founders can better assess:

• Which regulatory pathway may be appropriate
• What level of clinical evidence may be expected
• How risk classification could impact timelines

This perspective helps align development plans with real-world expectations.

Strengthening go to market thinking

Product development often gets most of the attention in early-stage startups, but go to market strategy is just as important.

I-Corps encourages teams to think through how their product will actually reach customers. This includes:

• Defining target customer segments
• Exploring pricing and reimbursement models
• Understanding purchasing dynamics
• Identifying potential sales channels

By the end of the program, teams typically have a clearer and more realistic path to market.

Practical benefits for founders

In addition to the learning experience, I-Corps provides several tangible benefits:

• Non-dilutive funding, often around fifty thousand dollars at the national level
• Access to experienced mentors and instructors
• A structured framework for testing market assumptions
• Stronger positioning for SBIR and STTR funding
• Increased credibility with investors and partners

These advantages can make a meaningful difference at the earliest stages of a company.

Where I-Corps fits in the development journey

I-Corps is most useful before significant resources are committed to product development.

It is a strong fit for teams that are still refining their understanding of the problem, the customer, or the market.

After completing the program, startups are usually better prepared to:

• Move into product development and engineering
• Establish design controls and documentation
• Engage with regulatory pathways more confidently
• Plan for clinical validation and commercialization

How it compares to incubators

I-Corps and medtech incubators support startups in different ways.

I-Corps is short and focused on early validation, while incubators typically provide longer-term support and broader resources.

Key differences include:

• I-Corps focuses on customer discovery, while incubators provide mentorship and infrastructure
• I-Corps is a short, intensive program, while incubators often run for several months
• I-Corps provides non-dilutive funding, while incubators may offer a mix of resources and capital

Many founders participate in I-Corps before joining an incubator so they can make better use of those later opportunities.

Final thoughts

The I-Corps program has become an important starting point for many medtech startups. It helps founders challenge their assumptions and understand the realities of healthcare adoption.

The core idea is simple. Before investing heavily in building a solution, make sure the problem is real and worth solving.

For teams willing to engage deeply with the process, I-Corps provides a practical way to reduce risk and build a stronger foundation for product development and commercialization.

If you want, I can also add SEO metadata, suggested keywords, or internal linking ideas to tie this more directly into Ontogen’s site.

‍